Abstract | BACKGROUND: METHODS:
Fetuin-A concentration endocrine-metabolic markers and hepatovisceral fat were measured longitudinally in 35 PCOS girls [age, 16 yr; body mass index (BMI), 23 kg/m2] randomized to receive either oral contraception [ethinylestradiol- levonorgestrel (n = 18)] or a low-dose combination of spironolactone, pioglitazone, and metformin (SPIOMET, n = 17) over 12 months. Healthy adolescent girls (age- and BMI-matched) were used as controls (n = 25). RESULTS: Pretreatment fetuin-A serum levels in PCOS girls were lower than those in controls. After 12 months on treatment, fetuin-A raised to control levels only in the SPIOMET subgroup (P = 0.009, versus oral contraception); this increase was paralleled by a healthier metabolic profile with less hepatic fat (by MRI); baseline serum fetuin-A as well as the changes over 12 months was inversely related to hepatic adiposity. CONCLUSIONS:
|
Authors | Marta Díaz, José Miguel Gallego-Escuredo, Abel López-Bermejo, Francis de Zegher, Francesc Villarroya, Lourdes Ibáñez |
Journal | International journal of endocrinology
(Int J Endocrinol)
Vol. 2018
Pg. 4192940
( 2018)
ISSN: 1687-8337 [Print] Egypt |
PMID | 30123261
(Publication Type: Journal Article)
|